Testing KK2260 in patients with advanced or metastatic solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study evaluates the safety and tolerability of KK2260 in patients with advanced or metastatic solid tumors. The study is divided into two parts: Part 1a focuses on determining the maximum tolerated dose (MTD) of KK2260, while Parts 1b and 2 will assess various dosing regimens and their efficacy based on cancer type. Patients will be monitored for safety and treatment response throughout the study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\<Common Inclusion Criteria for Part 1a, Part 1b, and Part 2

1. Patients who have given informed written consent.
2. Male or female subjects ≥18 years of age, at time of signing informed consent.
3. Subjects who are refractory to standard treatment, intolerant of standard treatment, for whom standard treatment does not exist, or who have refused standard treatment.
4. Patients with measurable disease according to RECIST version 1.1
5. Patients who have had the certaion periods between the date of completion of prior therapy and the date of enrollment
6. Subjects who agree to have a tumor biopsy as part of the baseline examination. Patients who have difficulty in performing a tumour biopsy and have agreed to submit a previously collected stored specimen.
7. Patients with an ECOG PS of 0 or 1 at baseline.
8. Patients with haematopoietic, hepatic, renal, cardiac and respiratory functions that meet certain criteria in a baseline test.

\<Additional Inclusion Criteria for Part 1a

1\) Patients with pathologically diagnosed advanced or metastatic solid tumors.

\<Additional Inclusion Criteria for Part 1b

1. Patients with pathologically diagnosed with advanced or metastatic esophageal cancer, or advanced or metastatic head and neck cancer whose primary site of origin is the oral cavity, oropharynx, hypopharynx, larynx, nasal cavity, or paranasal sinuses.
2. Patients with pathologically diagnosed squamous cell carcinoma.
3. Patients who agree to undergo tumor biopsy after administration.

\<Additional Inclusion Criteria for Part 2a

1. Patients with pathologically diagnosed with advanced or metastatic esophageal cancer.
2. Patients with pathologically diagnosed squamous cell carcinoma.
3. Patients who agree to undergo tumor biopsy after administration.

\<Additional Inclusion Criteria for Part 2b

1. Patients with advanced or metastatic head and neck cancer whose primary site of origin is the oral cavity, oropharynx, hypopharynx, larynx, nasal cavity, or paranasal sinuses.
2. Patients with pathologically diagnosed squamous cell carcinoma.
3. Patients who agree to undergo tumor biopsy after administration.

Exclusion Criteria:

\<Common Exclusion Criteria to Part 1 and Part 2\>

1. Patients with central or brain pia mater metastases that are untreated and symptomatic or that require treatment.
2. Patients with concurrent multiple or synchronous cancers, or with iatrogenic multiple or synchronous cancers with a disease-free interval of 5 years or less.
3. Patients receiving continuous systemic administration of steroids or other immunosuppressive drugs.
4. Patients who have had a Grade 3 or higher allergic reaction to an antibody agent or an additive of the study drug.
5. Patients who have not recovered to Grade 1 or below from adverse events caused by previously administered anticancer therapy.
6. Patients with active interstitial lung disease or a history of active interstitial lung disease.
7. Patients with infectious diseases requiring systemic treatment.
8. Patients with a fever of 38.0°C or higher at the time of registration.
9. Patients who test positive for Hepatitis B virus antigen or antibody, Hepatitis C virus antibody, or HIV antibody in a baseline test.

Where it's running

• Aichi Cancer Center Hospital
  Nagoya, Aichi-ken, Japan Recruiting
• National Cancer Center Hospital East
  Kashiwa, Chiba, Japan Recruiting
• Shikoku Cancer Center
  Matsuyama, Ehime, Japan Recruiting
• Hiroshima University Hospital
  Hiroshima, Hiroshima, Japan Recruiting
• Kobe University Hospital
  Kobe, Hyōgo, Japan Recruiting
• Kanagawa Cancer Center
  Yokohama, Kanagawa, Japan Recruiting

Study contacts

• Study coordinator: Kyowa Kirin Co., Ltd.
• Email: clinical.info.jp@kyowakirin.com
• Phone: +81-3-5205-7200

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SHY-ONC6: a new anti-cancer drug tested in adults with advanced solid tumors

  This early-phase study tests SHY-ONC6 to see if it is safe and can help people with advanced solid tumors after standard therapies have failed.

  Recruiting at 3 sites Phase 1 SHY Therapeutics · Scottsdale, Arizona and 2 other locations · NCT07705334

• Precision-matched donor CAR-NK cell therapy targeting one or two tumor antigens for advanced solid tumors

  This trial tests banked donor CAR‑NK cell infusions matched to the antigens in an adult's tumor to see if they are safe and can shrink advanced solid tumors.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07510828

• KGX101 alone and with envafolimab for advanced or metastatic solid tumors

  This trial will test whether KGX101 by itself or combined with envafolimab is safe and tolerable for adults in China with advanced or metastatic solid tumors.

  Recruiting at 3 sites Phase 1 Kangabio AUSTRALIA LTD PTY · Beijing, Beijing Municipality and 2 other locations · NCT07260305

• TAK-188 for adults with advanced or metastatic solid tumors

  This trial will test whether TAK-188, a drug that targets CCR8 to remove immune-suppressing cells in tumors, helps adults with advanced or metastatic solid tumors whose cancer has not improved after prior treatments.

  Recruiting at 15 sites Phase 1/2 Takeda · Santa Monica, California and 14 other locations · NCT07205718

• Testing LNCB74 in patients with advanced solid tumors

  This study is testing a new treatment called LNCB74 to see if it's safe and how well it works for people with advanced solid tumors like ovarian, breast, and lung cancer.

  Recruiting at 14 sites Phase 1 LigaChem Biosciences, Inc. · Newport Beach, California and 16 other locations · NCT06774963

• Evaluating a new treatment for advanced or metastatic solid tumors

  This study is testing a new treatment for people with advanced or metastatic solid tumors to see if it is safe and effective after they have tried other therapies.

  Recruiting at 11 sites Phase 1 Day One Biopharmaceuticals, Inc. · New Haven, Connecticut and 10 other locations · NCT06752681

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.